Evidence map›Paper›PMID 41432874›Full record

ArticleDiscover oncology2025

M2 macrophage infiltration associated with CXCL8 predicts grade 4 prognosis and differentiates glioma grades.

Wei-Hsiu Liu, Cheng-Chin Lee, Yu-Jia Chang, Ai-Wei Lee, Chien-Yu Huang, Tuan Ngoc Anh Vo, Yung-Fu Wu, Jang-Chun Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wei-Hsiu Liu *Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical University, Taipei, 11490, Taiwan, ROC.
Cheng-Chin LeeGraduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan, ROC.
Yu-Jia ChangGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, ROC.
Ai-Wei Lee *Department of Anatomy and Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, ROC.ORCID http://orcid.org/0000-0002-4463-7391
Chien-Yu HuangSchool of Medicine, National Tsing Hua University, Hsinchu, 300044, Taiwan, ROC.
Tuan Ngoc Anh VoDepartment of Manufacturing, Faculty of Mechanical Engineering, Ho Chi Minh City University of Technology (HCMUT), VNU-HCM, Ho Chi Minh City, Vietnam.
Yung-Fu WuDepartment of Medical Research, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan, ROC.
Jang-Chun LinDepartment of Radiation Oncology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, 23561, Taiwan, ROC. jangchunlin4554@edusbm.cn.ORCID http://orcid.org/0000-0003-2784-5604

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aims to improve glioma-WHO grading by identifying biomarkers distinguishing Gr. 4 from Gr. 3 gliomas and exploring their immune-related prognostic significance.

methodsWe analyzed differentially expressed genes (DEGs) between Gr. 3 and Gr. 4 gliomas using the GSE4290 (31 Gr. 3, 77 Gr. 4) and GSE109857 (34 Gr. 3, 89 Gr. 4) datasets. Key genes were identified through protein-protein interaction (PPI) network and KEGG pathway enrichment analyses. These genes underwent survival analysis and validation using data from The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA).

resultsAmong 23 key genes, CXCL8/IL8 and THBS1 were validated in TCGA and CGGA datasets. CXCL8 significantly correlated with progression-free survival (PFS) in Gr. 4 gliomas (p = 0.028) but not Gr. 3 (p = 0.522). ROC analysis confirmed its diagnostic accuracy (AUC: 0.899 in TCGA, 0.644 in CGGA). Immune infiltration analysis linked CXCL8 to macrophages (p < 0.001) and neutrophils (p < 0.001), particularly M2 macrophages.

conclusionsCXCL8 has a significant impact on disease prognosis and tumor immunity in Gr. 4 gliomas. The association of CXCL8 with M2 macrophage infiltration suggests that CXCL8-related markers could serve as potential prognostic biomarkers for differentiating between Gr. 4 and Gr. 3 gliomas.

Indexed as

CXCL8/IL8GliomaM2 macrophagePrognostic biomarker

Identifiers

PMID41432874
PMCPMC12728105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.